GlaxoSmithKline PLC (GSK): Price and Financial Metrics

GlaxoSmithKline PLC (GSK)

Today's Latest Price: $36.04 USD

0.14 (-0.39%)

Updated Oct 20 7:00pm

Add GSK to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

GSK Stock Summary

  • With a market capitalization of $97,380,319,359, Glaxosmithkline Plc has a greater market value than 98.15% of US stocks.
  • GSK's went public 34.31 years ago, making it older than 92.41% of listed US stocks we're tracking.
  • The volatility of Glaxosmithkline Plc's share price is greater than that of only 1.94% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to GSK, based on their financial statements, market capitalization, and price volatility, are MMM, CAT, IBM, PDD, and ZTS.
  • GSK's SEC filings can be seen here. And to visit Glaxosmithkline Plc's official web site, go to

GSK Stock Price Chart Interactive Chart >

Price chart for GSK

GSK Price/Volume Stats

Current price $36.04 52-week high $48.25
Prev. close $36.18 52-week low $31.43
Day low $35.78 Volume 5,306,397
Day high $36.24 Avg. volume 3,770,184
50-day MA $38.74 Dividend yield 5.36%
200-day MA $40.87 Market Cap 90.41B

GlaxoSmithKline PLC (GSK) Company Bio

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company’s wellness products include Panadol and Panadol Cold & Flu, ENO and Tums - antacids, and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate - treatment of nicotine withdrawal, Sensodyne - to ttreat and prevent dental sensitivity, Polident, Poligrip, and Corega to enhance comfort of fitted denture, and Aquafresh for the prevention of gum disease and bad breath. The company was founded in 1935 and is based, the United Kingdom.

GSK Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$36.04$21.74 -40%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Glaxosmithkline Plc. To summarize, we found that Glaxosmithkline Plc ranked in the 34th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Glaxosmithkline Plc, consider:

  • The company has produced more trailing twelve month cash flow than 93.01% of its sector Healthcare.
  • Glaxosmithkline Plc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 24.08% of tickers in our DCF set.
  • GSK's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than merely 24.08% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Glaxosmithkline Plc? See CRL, ENDP, IQV, MD, and PRGO.

GSK Latest News Stream

Event/Time News Detail
Loading, please wait...

GSK Latest Social Stream

Loading social stream, please wait...

View Full GSK Social Stream

Latest GSK News From Around the Web

Below are the latest news stories about Glaxosmithkline Plc that investors may wish to consider to help them evaluate GSK as an investment opportunity.

US appeals court revives Glaxo US$235.5 million verdict against Teva

A federal appeals court on Friday reinstated a 2017 jury verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than US$235 million for infringing a patent for its blood pressure drug Coreg.

Channel NewsAsia | October 2, 2020

Global Pneumonia Therapeutics Market Trajectory & Analytics Report 2020 Featuring Abbott Labs, Allergan, Bayer, GlaxoSmithKline, Lupin Pharma, Merck & Co, Novartis & Pfizer -

DUBLIN--(BUSINESS WIRE)--The "Pneumonia Therapeutics - Global Market Trajectory & Analytics" report has been added to's offering. Global Pneumonia Therapeutics Market to Reach US$22.5 Billion by the Year 2027 Amid the COVID-19 crisis, the global market for Pneumonia Therapeutics estimated at US$14.5 Billion in the year 2020, is projected to reach a revised size of US$22.5 Billion by 2027, growing at a CAGR of 6.5% over the analysis period 2020-2027. Drugs, one of the

Business Wire | October 2, 2020

Global Leigh Syndrome Treatment Market 2020: Growth, Emerging Trends And Forecast By GlaxoSmithKline Plc, Brother Enterprises, Huazhong, Zhejiang Tianxin, Stryker Corporation, Zimmer Biomet Holdings, Inc

A new research study from “Data Bridge Market Research” with title Leigh Syndrome Treatment Insights 2020GlaxoSmithKline Plc, Brother Enterprises, Huazhong, Zhejiang Tianxin, Stryker Corporation, Zimmer Biomet Holdings, Inc., Wright Medical Technology, Inc., Integra LifeSciences Holdings Corporation among other domestic

OpenPR | October 1, 2020

Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Top Emerging Players are Ablyn, Aryogen Farmad, CASI Pharmaceuticals Inc., CELGENE CORPORATION, Celltrion Inc., GlaxoSmithKline plc

Tumor Necrosis Factor (TNF) Inhibitor Drugs Market By Drug (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, Pipeline Analysis), Application (Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease, Ankylosing Spondylitis, Crohn’s Disease, Plaque Psoriasis, Ulcerative Colitis, Hidradenitis Suppurativa, Juvenile Arthritis, Uveitis, Others), Product (Humira, Enbrel, Remicade,

OpenPR | September 30, 2020

Global Fabry Disease Market To See prominent Growth By 2027||Takeda Pharmaceutical Company Limited., GlaxoSmithKline Plc, Protalix Inc., JCR Pharmaceuticals Co., Ltd

A new market study is released on Global Fabry Disease market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This Fabry Disease market report

OpenPR | September 30, 2020

Read More 'GSK' Stories Here

GSK Price Returns

1-mo -5.68%
3-mo -9.53%
6-mo -13.27%
1-year -11.20%
3-year 2.73%
5-year 8.72%
YTD -20.53%
2019 29.12%
2018 13.70%
2017 -3.03%
2016 -1.10%
2015 -0.27%

GSK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GSK Dividend History

Continue Researching GSK

Here are a few links from around the web to help you further your research on Glaxosmithkline Plc's stock as an investment opportunity:

Glaxosmithkline Plc (GSK) Stock Price | Nasdaq
Glaxosmithkline Plc (GSK) Stock Quote, History and News - Yahoo Finance
Glaxosmithkline Plc (GSK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8331 seconds.